BI 113608
Alternative Names: BI-113608Latest Information Update: 11 Mar 2016
At a glance
- Originator Boehringer Ingelheim
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 01 May 2014 Boehringer Ingelheim completes a phase I trial in Chronic obstructive pulmonary disease in Germany (NCT01958008)
- 01 May 2014 Boehringer Ingelheim completes a phase I trial in Healthy Asian & Caucasian volunteers in South Korea (NCT01922349)
- 01 Oct 2013 Boehringer Ingelheim plans a phase I trial in Chronic obstructive pulmonary disease in Germany (NCT01958008)